“Machine learning at GSK involves taking complex datasets generated at scale and answering very challenging biological questions,” says Kim Branson, senior vice president and global head of AI and Machine Learning at GSK. “The long sequence length capability enables us to examine a particular gene in the context of tens of thousands of surrounding genes. We know that surrounding genes have an impact on gene expression, but we have never before been able explore this within AI.”
https://www.cerebras.net/press-release/cerebras-systems-enables-gpu-impossible-long-sequence-lengths-improving-accuracy-in-natural-language-processing-models/
Learn more about training long sequence lengths with a Cerebras CS-2: https://www.cerebras.net/blog/context-is-everything-why-maximum-sequence-length-matters/
Learn more about how GSK is using the Cerebras CS-2 to accelerate their drug discovery and AI efforts: https://www.cerebras.net/cerebras-customer-spotlight-overview/spotlight-glaxosmithkline/
Add comment